Clinical Trials Logo

Respiratory Tract Infections clinical trials

View clinical trials related to Respiratory Tract Infections.

Filter by:

NCT ID: NCT02592902 Completed - Clinical trials for Recurrent Respiratory Papillomatosis

Recurrent Respiratory Papillomatosis and Extraesophageal Reflux

Start date: April 2014
Phase: N/A
Study type: Interventional

The purpose of the study was to determine, whether patients with recurrent respiratory papillomatosis (RRP) suffer from extra oesophageal reflux more often than patients with laryngeal cyst (control group).

NCT ID: NCT02563106 Completed - Clinical trials for Clostridium Difficile

A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI

Start date: October 2015
Phase: Phase 2
Study type: Interventional

A Phase 2b Parallel-Group, Double-Blind, Placebo-Controlled, Multicenter Study of SYN-004 Compared to Placebo for the Prevention of Clostridium difficile Infection (CDI) in Hospitalized Patients receiving IV ceftriaxone with a Diagnosis of a Lower Respiratory Tract Infection (LRTI).

NCT ID: NCT02561871 Completed - Clinical trials for Respiratory Tract Infections

A Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad26.RSV.FA2 Followed by Ad35.RSV.FA2 in Healthy Adult Volunteers

Start date: September 2015
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety and tolerability of intramuscular prime-boost regimens of Ad26.RSV.FA2 given either once or twice followed by Ad35.RSV.FA2 (human adenovirus-vectored vaccine candidate) in healthy participants.

NCT ID: NCT02558062 Completed - Clinical trials for Bacterial Respiratory Infections

Microdosing of BAC ONE to the Distal Lung

BAC ONE
Start date: May 2016
Phase: Early Phase 1
Study type: Interventional

Critically ill patients are often ventilated in dedicated critical care units to provide respiratory support. Despite best practice patients can often develop a condition called adult respiratory distress syndrome (ARDS), which is characterised by deterioration in their respiratory function, and changes on chest x-ray. The correct management for ARDS is identifying the underlying condition causing the deterioration and identifying appropriate targeted therapy. One such cause is pneumonia, caused by a bacterial infection in the lungs of a ventilated patient. The patients may have been ventilated due to pneumonia but they may also develop pneumonia whilst ventilated. Ventilator associated pneumonia (VAP) has significant mortality. Despite all the clinical and laboratory data at the investigators' disposal there remains great difficulty in the accurate diagnosis of pneumonia and therefore treatment is often given empirically. Therefore, there is an urgent clinical need for accurate methods to diagnose the presence of bacteria deep in the lung in ventilated critically ill patients. As such, the investigating team have developed and synthesised an imaging agent called BAC ONE. BAC ONE will be instilled directly into the lungs of 12 patients (with and without lung infection) to assess whether it can label bacteria in the human lung.

NCT ID: NCT02554383 Completed - Clinical trials for Respiratory Tract Infections

Efficacy of Antibiotics in Children With Acute Sinusitis: Which Subgroups Benefit?

Start date: February 2016
Phase: Phase 3
Study type: Interventional

The objective of this trial is to determine whether certain subgroups of children with acute sinusitis exist in whom antibiotic therapy can be appropriately withheld.

NCT ID: NCT02512614 Completed - Fever Clinical Trials

Evaluation of Novel Antimicrobial Hand Towels

Start date: March 2012
Phase: Phase 2/Phase 3
Study type: Interventional

In March 2012, the investigators initiated a prospective, cluster-randomized, controlled field trial in Kisumu County, located in an area in western Kenya which has the highest under-five mortality rate in Kenya with 149 childhood deaths per 1,000 live births 9. The study was designed to evaluate the effectiveness of an antimicrobial hand towel (hereafter referred to as towel) in preventing diarrheal diseases, acute respiratory infections, self-reported fever, and skin infections in children <2 years old.

NCT ID: NCT02491684 Completed - Asthma Clinical Trials

A Study in Asthma Patients to Evaluate Efficacy, Safety and Tolerability of 14 Days Once Daily Inhaled Interferon Beta-1a After the Onset of Symptoms of an Upper Respiratory Tract Infection

INEXAS
Start date: July 21, 2015
Phase: Phase 2
Study type: Interventional

A study to investigate if inhaled Interferon beta-1a is safe and tolerated, and can prevent or reduce the severity of asthma attacks when administered to asthma patients at the onset of symptoms of common cold or influenza

NCT ID: NCT02491164 Completed - Clinical trials for Respiratory Infections

Exploratory Study of Intrapulmonary Microdosing of Gram-negative Optical Imaging Detection Probe

BAC TWO
Start date: April 2016
Phase: Early Phase 1
Study type: Interventional

Critically ill patients are often ventilated in dedicated critical care units to provide respiratory support. Despite best practice patients can often develop a condition called adult respiratory distress syndrome (ARDS), which is characterised by deterioration in their respiratory function, and changes on chest x-ray. The correct management for ARDS is identifying the underlying condition causing the deterioration and identifying appropriate targeted therapy. One such cause is pneumonia, caused by a bacterial infection in the lungs of a ventilated patient. The patients may have been ventilated due to pneumonia but they may also develop pneumonia whilst ventilated. Ventilator associated pneumonia (VAP) has significant mortality. Despite all the clinical and laboratory data at the investigators' disposal there remains great difficulty in the accurate diagnosis of pneumonia and therefore treatment is often given empirically. Therefore, there is an urgent clinical need for accurate methods to diagnose the presence of bacteria deep in the lung in ventilated critically ill patients. As such, the investigating team have developed and synthesised an imaging agent called BAC TWO. BAC TWO will be instilled directly into the lungs of 12 patients to assess whether it can label gram-negative bacteria in the human lung.

NCT ID: NCT02484417 Completed - Clinical trials for Upper Respiratory Tract Infection

Respiratory Syncytial Virus Human Challenge in Healthy Adult Volunteers

Start date: July 21, 2015
Phase: Phase 1
Study type: Interventional

Background: - Respiratory syncytial virus (RSV) can cause respiratory infections. Some of these can be life-threatening, especially in young children, the elderly, and people with weak immune systems. Researchers want to study RSV infection in a hospital setting in healthy adults. They want to use what they learn to test new treatments or vaccines in the future. Objectives: - To study how the body responds to RSV. Eligibility: - Healthy volunteers ages 18-50 Design: - Participants will be screened under another protocol. - Participants will have: - Medical history - Physical exams - EKG. Heart rhythm is measured with small sticky patches on the chest, arms, and legs. - Chest x-ray - Pulmonary function tests. This measures how much air a person can move into and out of the lungs. - Blood and urine tests - Nasal washes and/or nasal swabs. For the wash, the nose will be rinsed with a sterile liquid. For the swab, the inside of the nostril will be rubbed with a cotton swab. - Participants will have two, possibly three, follow-up outpatient visits, approximately 1, 2 and 6 months after receiving the dose of RSV. - Participants will stay in the hospital under isolation for 7 or more days after getting the virus. - The average stay is 10 days. Participants cannot leave the isolation unit. They cannot have visitors. - The virus should cause a mild to medium cold. - Participants will fill out a symptom card every day in the hospital and for 1 month after. - Participants will have 2 follow-up visits, 28 and 56 days after leaving the hospital. - Female participants who are sexually active must remain abstinent or use an effective form of birth control for 1 month before and after getting the virus.

NCT ID: NCT02473796 Completed - Malaria Clinical Trials

Home Based Child Care to Reduce Mortality and Malnutrition in Tribal Children of Melghat, India: CRCT

HBCC
Start date: January 2004
Phase: N/A
Study type: Interventional

Melghat is poorly developed tribal area in India with very high child mortality & malnutrition prevalence (grossly inadequate medical facilities). Important health problems. Malnutrition , Pneumonia, Tuberculosis, Anaemia, Malaria, Diarrhoea, Premature and L. B. W. babies, Neonatal sepsis, Feeding problem, Birth asphyxia. The investigators developed a Home Based Child Care (HBCC) model to reduce neonatal mortality rate (NMR), infant mortality rate (IMR), under 5 mortality rate (U5MR) and severe malnutrition(SM) in this region. Melghat. Need of project : Melghat is known for highest U5MR in Maharashtra. Overall aims and importance of the research:. The results obtained in this area will be applicable for reducing children mortality and malnutrition in other parts of Melghat and all other tribal areas of India. Methodology: RCT-Home based child care (HBCC) by trained village health workers .(ARI, Diarrhoea, Malaria clinically & Neonatal care) in 19 villages. Strengthening of existing government ICDS and health system. Melghat. Need of project : Melghat is known for highest U5MR in Maharashtra. Overall aims and importance of the research:. The results obtained in this area will be applicable for reducing children mortality and malnutrition in other parts of Melghat and all other tribal areas of India. Methodology: RCT- (HBCC) by trained village health workers .(ARI, Diarrhoea, Malaria clinically & Neonatal care) in 19 villages.